Aspirin for primary prevention of cardiovascular disease

Area of Science:

• Cardiology
• Preventive Medicine
• Pharmacology

Background:

• Aspirin is widely used for secondary prevention of cardiovascular disease (CVD).
• Its role in primary CVD prevention, especially in individuals without a history of CVD, is under ongoing investigation.
• Balancing the benefits of aspirin against its risks, particularly bleeding, is critical for primary prevention decisions.

Purpose of the Study:

• To evaluate the net benefit of aspirin for primary cardiovascular disease (CVD) prevention.
• To determine if the benefits of aspirin in individuals without established CVD outweigh the associated risks.
• To provide guidance on the individualized decision-making process for initiating aspirin therapy in primary CVD prevention.

Main Methods:

• Review of current data on aspirin efficacy and safety in primary CVD prevention.
• Analysis of the risk-benefit profile, comparing cardiovascular event reduction with bleeding risks.
• Emphasis on individualized risk assessment using validated tools.

Main Results:

• Evidence for aspirin's benefit in primary CVD prevention is not conclusive, with bleeding risks being a significant concern.
• The decision to use aspirin for primary prevention requires careful consideration of an individual's absolute CVD risk versus their absolute bleeding risk.
• Cost-benefit analyses and locally developed risk assessment tools are recommended.

Conclusions:

• Continuous aspirin use for primary CVD prevention lacks sufficient evidence to consistently outweigh adverse events like bleeding.
• Initiating aspirin therapy for primary prevention should be an individualized clinical judgment, balancing potential benefits against bleeding risks.
• Physician training in CVD risk calculation and consideration of patient preferences are essential for informed decision-making.